Published in Clin Infect Dis on November 01, 2016
Linezolid dose that maximizes sterilizing effect while minimizing toxicity and resistance emergence for tuberculosis. Antimicrob Agents Chemother (2017) 0.75
Efficient measurement and factorization of high-order drug interactions in Mycobacterium tuberculosis. Sci Adv (2017) 0.75
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med (2003) 14.40
Comparison of MB-Check, BACTEC, and egg-based media for recovery of mycobacteria. J Clin Microbiol (1992) 4.55
Comparison of the Mycobacteria Growth Indicator Tube (MGIT) with radiometric and solid culture for recovery of acid-fast bacilli. J Clin Microbiol (1997) 4.01
A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis (2008) 3.77
Liquid vs. solid culture for tuberculosis: performance and cost in a resource-constrained setting. Int J Tuberc Lung Dis (2010) 2.59
Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients. Int J Tuberc Lung Dis (2010) 2.00
Time to detection of Mycobacterium tuberculosis in BACTEC systems as a viable alternative to colony counting. Int J Tuberc Lung Dis (2008) 1.85
Time to detection of Mycobacterium tuberculosis in sputum culture correlates with outcome in patients receiving treatment for pulmonary tuberculosis. Chest (1998) 1.79
Comparison of the mycobacteria growth indicator tube with MB redox, Löwenstein-Jensen, and Middlebrook 7H11 media for recovery of mycobacteria in clinical specimens. J Clin Microbiol (1999) 1.72
Quantitative sputum bacillary load during rifampin-containing short course chemotherapy in human immunodeficiency virus-infected and non-infected adults with pulmonary tuberculosis. Int J Tuberc Lung Dis (2000) 1.51
New approaches and emerging technologies in the diagnosis of childhood tuberculosis. Paediatr Respir Rev (2007) 1.47
Geographic differences in time to culture conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa. PLoS One (2011) 1.38
Clinical evaluation of the Mycobacteria Growth Indicator Tube (MGIT) compared with radiometric (Bactec) and solid media for isolation of Mycobacterium species. J Med Microbiol (1998) 1.19
Linezolid pharmacokinetics in pediatric patients: an overview. Pediatr Infect Dis J (2003) 1.17
In vitro and in vivo efficacy of β-lactams against replicating and slowly growing/nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother (2013) 1.10
Rapid cytolysis of Mycobacterium tuberculosis by faropenem, an orally bioavailable β-lactam antibiotic. Antimicrob Agents Chemother (2014) 0.99
Faropenem: review of a new oral penem. Expert Rev Anti Infect Ther (2007) 0.98
Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis. Clin Infect Dis (2014) 0.95
Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study. J Antimicrob Chemother (2014) 0.92
Tuberculous Pericarditis is Multibacillary and Bacterial Burden Drives High Mortality. EBioMedicine (2015) 0.92
A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies. EBioMedicine (2016) 0.85
Activity of faropenem against cephalosporin-resistant Enterobacteriaceae. J Antimicrob Chemother (2007) 0.85
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. Antimicrob Agents Chemother (2010) 0.79
Beta-lactamase stability of faropenem. Chemotherapy (2003) 0.79
[Efficacy and safety of faropenem in pediatric patients with bacterial infectious diseases]. Jpn J Antibiot (2008) 0.78
Faropenem medoxomil. Ann Pharmacother (2007) 0.78
Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes. Clin Infect Dis (2015) 1.18
Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm. Clin Infect Dis (2015) 1.00
Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments. Clin Infect Dis (2015) 0.96
Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests. Clin Infect Dis (2016) 0.82
Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks. Clin Infect Dis (2016) 0.75
A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground. Clin Infect Dis (2016) 0.75
Linezolid for Infants and Toddlers With Disseminated Tuberculosis: First Steps. Clin Infect Dis (2016) 0.75
Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo. Clin Infect Dis (2016) 0.75
Partnerships to Design Novel Regimens to Treat Childhood Tuberculosis, Sui Generis: The Road Ahead. Clin Infect Dis (2016) 0.75
Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis. Clin Infect Dis (2017) 0.75
On the antibacterial and sterilizing effect of benzylpenicillin in tuberculosis. Antimicrob Agents Chemother (2017) 0.75